The presentation will be for the entire trial, not simply reading an abstract. It's a virtual presentation but should include K-M plots and all the other things normally seen in a presentation of an entire trial for peer review. This is peer review regardless of whether it's virtual, or not. After the presentation, the company should be free to discuss the trial with investors as it will have been peer reviewed.
News 
Market Data 
Discover 
AI
